Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. Tolaney SM, de Azambuja E, Kalinsky K, Loi S, et al. N Engl J Med 2026;394:354-366.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tolaney SM, de Azambuja E, Kalinsky K, Loi S, et al. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. N Engl J Med 2026;394:354-366.
PMID: 41564397